Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: Insights from the faSScinate clinical trial in systemic sclerosis
Denton CP et al. Ann Rheum Dis 2018. doi: 10.1136/annrheumdis-2018-213031
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.